Harrow partners with healthcare market access technology platforms to support launch of Vevye

(Image Credit: AdobeStock/Piman Khrutmuang)

Harrow announced it has partnered with 3 leading healthcare technology platforms to expand US availability of cyclosporine ophthalmic solution 0.1% (Vevye), a patented, non‑preserved, twice-daily (BID) dosed, ophthalmic solution prescription drug based on a “water-free” semifluorinated alkane (SFA) eyedrop technology.

According to a company news release, the solution is dispensed in a 10 microliter drop, is the first and only cyclosporine-based product indicated for treating both signs and symptoms of dry eye disease (DED).

Harrow’s 3 market access partnerships for VEVYE include:

• PhilRx, a patient access platform that provides end-to-end visibility into the entire prescription life cycle, starting when the eyecare professional (ECP) writes a prescription electronically to PhilRx directly from their electronic health record (EHR). Using the PhilRx platform simplifies the prior authorization process (PA) for physicians by providing one-click submission of PAs, streamlining the insurance coverage process for patients, and increasing the chances of insurance reimbursement. PhilRx offers a variety of patient benefits, including best price, fast free shipping, text refill reminders, and best‑in-class customer service.
• Apollo Care, a comprehensive program designed to establish and manage copay program deployment, optimizing patient access and affordability of cyclosporine ophthalmic solution.
• PARx Solutions, a web-based technology stack that helps prescribers – free of charge – overcome cumbersome, frustrating, and time-consuming challenges resulting from prior authorizations, thus ensuring that patients get the medication prescribed.

Mark L Baum, chairman and CEO of Harrow, pointed out in the news release the company was founded on a commitment to patient access.

“Our 360-degree approach to market access for Vevye, including these new partnerships with PhilRx, Apollo Care, and PARx, is designed to ensure that all patients who can benefit from VEVYE and who are prescribed Vevye – can get Vevye,” he said in the news release.

Baum also noted the company notes that cyclosporine ophthalmic solution represents an important new prescription choice in the US dry eye disease market.

“We are excited to streamline the prior authorization process, guiding patients through their insurance coverage and ensuring competitive pricing – with minimum hassle,” he said in the news release. “Harrow’s Vevye market access program perfectly aligns with our commitment to providing physicians and their patients with innovative and affordable ophthalmic pharmaceutical products and the Harrow team eagerly anticipates the availability of Vevye – next week.”

Reference:

1. Harrow partners with Leading Healthcare Market Access Technology Platforms. Business Wire. January 3, 2024. Accessed January 3, 2024. https://www.businesswire.com/news/home/20240103973471/en/Harrow-Partners-with-Leading-Healthcare-Market-Access-Technology-Platforms.